The intricate interplay with the key signaling pathways of berberine (AMPK, SIRT1, and FGF21) opens avenues for the further exploration of its therapeutic potential in addressing metabolic disorders and obesity. The gene discussed is PRKAA1; the disease is obesity due to melanocortin 4 receptor deficiency.